• Hormone replacement therapy (HRT) for oestrogen deficiency symptoms in postmenopausal women [at least 6 months since last menses]. • Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis. (See also section 4.4) The experience treating women older than 65 years is limited.
• Hormone replacement therapy (HRT) for oestrogen deficiency symptoms in postmenopausal women [at least 6 months since last menses]. • Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis (see section 4.4) The experience treating women older than 65 years is limited.
Norgine B.V. and Merus Labs International Inc. are pleased to announce the closing of the plan of arrangement under the...
Osimertinib (OSI), also known as AZD9291, is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has been approved for the treatment of non-small cell lung cancer ...
In this review, we discuss the role of epithelial cells and the mechanisms underlying the fibrotic response in IPF, and highlight some promising therapeutic targets for these cells.
Osimertinib (AZD9291) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that has been approved for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC).